The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial.
C. Falandry
Honoraria - Schering-Plough
E. Brain
No relevant relationships to disclose
M. Bonnefoy
No relevant relationships to disclose
F. Mefti
No relevant relationships to disclose
A. Savoye
No relevant relationships to disclose
O. Rigal
Honoraria - GlaxoSmithKline; Janssen-Cilag; Sandoz
S. Oddou-Lagranière
No relevant relationships to disclose
C. El Kouri
No relevant relationships to disclose
L. Uwer
No relevant relationships to disclose
S. Abadie-Lacourtoisie
No relevant relationships to disclose
J. Cretin
No relevant relationships to disclose
J. Jacquin
No relevant relationships to disclose
G. Freyer
Honoraria - Schering-Plough